NuPathe
http://www.nupathe.com/Zecuity® transdermal patch to treat migraine headaches approved by the FDA in 2013. IPO (NASDAQ: PATH) completed in August 2010 and the company was acquired by Teva Pharmaceutical Industries Ltd. in February 2014.
Exited Portfolio Company
www.nupathe.com
Total raised: $28M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 26.09.2012 | - | $28M | - | - |
Mentions in press and media 11
| Date | Title | Description | Category | Author | Source |
| 17.01.2013 | NuPathe ge... | The approval for the Zecuity c... | - | - | medcitynew... |
| 09.10.2012 | Migraine p... | Anido replaced Jane Hollingswo... | - | - | medcitynew... |
| 26.09.2012 | Migraine p... | Armando Anido, the CEO of the ... | - | - | medcitynew... |
| 26.09.2012 | Abiomed: M... | Abiomed (NSDQ:ABMD) said it do... | - | MassDevice... | massdevice... |
| 26.07.2012 | Migraine p... | “My number one priority is cas... | - | - | medcitynew... |
| 25.07.2012 | Biopharmac... | Incoming CEO and board member ... | - | - | medcitynew... |
| 16.07.2012 | Migraine p... | Jane Hollingsworth, NuPathe’s ... | - | - | medcitynew... |
| 19.12.2011 | NuPathe CE... | Six years after NuPathe’s laun... | - | - | medcitynew... |
| 29.11.2011 | NB Therape... | Iontophoresis involves using e... | - | - | medcitynew... |
| 15.11.2011 | NuPathe to... | Migraine headaches affect abou... | - | - | medcitynew... |
Show more